Assessment Of The Effects Of Short and Long Term Use Of CPAP

NCT ID: NCT00592631

Last Updated: 2016-02-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-02-28

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We hypothesize that the nocturnal use of continuous positive airway pressure in adults and children with asthma will decrease airway reactivity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Deep inspirations have been shown to decrease the sensitivity of airways to narrowing (airway reactivity) after inhalation of agents that induce constriction of the bronchi in healthy adults. This response is absent in adult asthmatics; however, there is data demonstrating that use of continuous positive airway pressure (CPAP) for short periods of time may decrease airway reactivity in adult asthmatics. This suggests that although deep inspirations may not result in decreased airway reactivity, sustained lung inflation may lead to changes in asthmatic airway smooth muscle structure that lead to a decrease in airway reactivity. The purpose of our study is to determine whether short and long term use of CPAP in children and adults leads to decreased airway reactivity. If airway reactivity is decreased with CPAP, this may provide a novel therapeutic strategy for patients with asthma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPAP

Subjects will use CPAP of 8-12 during days 2 through 6 of the study.

Group Type EXPERIMENTAL

CPAP-Continuous Positive Airway Pressure

Intervention Type DEVICE

Cpap will be worn at night by subjects 6 to 7 days duration.

SHAM

Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.

Group Type SHAM_COMPARATOR

SHAM

Intervention Type DEVICE

SHAM will be worn at night by subjects 6 to 7 days duration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPAP-Continuous Positive Airway Pressure

Cpap will be worn at night by subjects 6 to 7 days duration.

Intervention Type DEVICE

SHAM

SHAM will be worn at night by subjects 6 to 7 days duration.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children 8-18 years of age scheduled to start CPAP for obstructive sleep apnea.
* Subjects can have clinically stable asthma, with no plans by their physician to change asthma therapy over the next month


* Adults 18-60 years of age, seen in adult Pulmonary Clinic for sleep related problems who may require treatment with nocturnal continuous positive pressure (CPAP), which will be determined by polysomnography(PSG) will be approached to participate in the study.


1. Juniper Score \<1.5
2. Baseline FEV1 \> or equal to 70%
3. Non-smoking for 6 months
4. Less than 10 pack year smoking history
5. No change in asthma medications for the last 2 months
6. Negative pregnancy test
7. Subject cannot have sleep apnea

Exclusion Criteria

Exclusions for Children category age 8-18 include:

1. Cyanotic congenital heart disease.
2. History of acute respiratory symptoms for 3 weeks prior to testing.
3. Inability to perform pulmonary function testing adequately.
4. Escalation in asthma medication at time of recruitment.
5. SaO2 \<93% while awake and breathing room air
6. Baseline FEV1 \<75% predicted

Exclusions for adults 18-60 include:

1. Gastro-Esophageal Reflux requiring Medical management.
2. Chronic Obstructive Pulmonary Disease.
3. Use of Supplemental Oxygen.
4. Ischemic Heart Disease or Hypertension requiring treatment with medications other than diuretics.
5. Use of systemic corticosteroid therapy during the past 6 months.
6. Acute Respiratory Illness in the previous 8 weeks.
Minimum Eligible Age

8 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Indiana University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert S. Tepper, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Mike Busk, MD

Role: STUDY_DIRECTOR

NIFS/ Indiana University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Riley Hospital for Children

Indianapolis, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Busk M, Busk N, Puntenney P, Hutchins J, Yu Z, Gunst SJ, Tepper RS. Use of continuous positive airway pressure reduces airway reactivity in adults with asthma. Eur Respir J. 2013 Feb;41(2):317-22. doi: 10.1183/09031936.00059712. Epub 2012 Jul 26.

Reference Type DERIVED
PMID: 22835615 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0405-16

Identifier Type: -

Identifier Source: secondary_id

0405-16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.